A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

NCT02963168 | Unknown Phase 1 FDA Drug

• 1 other identifier: KX-ORADOX-003
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 3

Brief Summary

This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.

Conditions

Solid Tumor

Outcome Measures

Primary Outcomes (1)

• The maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies

  The MTD will be the highest dose at which no more than 1 of 6 subjects experience a DLT during treatment and Oradoxel pharmacokinetics are acceptable.

  3 weeks

Secondary Outcomes (16)

• Safety assessment using AEs of Oradoxel

  Weekly, up to 24 months

• Safety assessment using SAEs of Oradoxel

  Weekly, up to 24 months

• Laboratory evaluation for hematology

  Weekly, up to 24 months

• Blood chemistry

  Weekly, up to 24 months

• Urine analysis

  Weekly, up to 24 months

Study Arms (1)

Oradoxel

EXPERIMENTAL

To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.

Drug: Oradoxel

Interventions

Oradoxel DRUG

oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets

Also known as: oral docetaxel + oral HM30181A

Oradoxel

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed written informed consent
• ≥18 years of age
• Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
• Docetaxel monotherapy is a reasonable treatment in the judgement of the Investigator
• Measurable disease as per RECIST v1.1 criteria
• Able to swallow oral medication as an intact dosage form
• Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ≥1500 cells/mm3, Platelet count ≥100 x 109/L, Hemoglobin (Hgb) ≥10 g/dL
• Adequate liver function as demonstrated by: Total bilirubin of \< upper limit of normal (ULN), Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤1.5 × ULN, Alkaline phosphatase (ALP) ≤2.5x ULN or \<5x ULN if bone metastases are present, Normal serum albumin
• Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine clearance\>60 mL/min as calculated by the Cockroft and Gault formula
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• Life expectancy of at least 3 months
• Willing to fast for 6 hours before and 2 hours after Oradoxel administration
• Females must be postmenopausal (\>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or, if sexually active, must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.
• Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

You may not qualify if:

• Currently taking a prohibited concomitant medication, other than a premedication, that are/is:
• Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampicin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study)
• Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication ≥1 week before dosing and remain off that medication through the end of PK sampling after the administration of the second study treatment
• An oral medication with a narrow therapeutic index known to be a P-gp substrate within 24 hours prior to start of dosing in the study
• Unresolved toxicity from prior chemotherapy (subjects must be recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products.
• Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study
• Received investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longer
• Require therapeutic use of anticoagulants
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant myocardial infarction within the last 6 months, unstable angina pectoris, clinically significant cardiac arrhythmia, bleeding disorder, chronic pulmonary disease requiring oxygen, or psychiatric illness/social situations that would limit compliance with study requirements
• Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption
• A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)
• Evidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome
• Any other condition which the Investigator believes would make participation in the study not acceptable

Sponsors & Collaborators

• Athenex, Inc.: lead

Study Sites (3)

Mayo Clinic

Phoenix, Arizona, 85054, United States

RECRUITING

Mayo Clinic

Rochester, Minnesota, 55905, United States

RECRUITING

Cancer Therapy & Research Center at UTHSCSA

San Antonio, Texas, 78229, United States

RECRUITING

MeSH Terms

Interventions

Docetaxel

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• David Cutler, MD

  Athenex, Inc.

  STUDY DIRECTOR

Central Study Contacts

E. Douglas Kramer, MD

CONTACT

908-340-6996; dkramer@athenex.com

Ildiko Bezi

CONTACT

908-340-6996; ibezi@athenex.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 7, 2016
• First Posted: November 15, 2016
• Study Start: April 20, 2017
• Primary Completion: March 30, 2020
• Study Completion: April 30, 2020
• Last Updated: October 17, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)